Here, a human recombinant form of IL-2, aldesleukin (Proleukin®, Novartis), is administered in varying low-dose strategies to patients with stable ischemic heart disease and acute coronary syndromes [159]. The gene discussed is IL2; the disease is coronary artery disorder.